Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. AstraZeneca

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

AstraZeneca

15 Jul 2021 17:30

RNS Number : 4287F
FTSE Russell
15 July 2021
Ā 

OĀ 

Ā 

Ā 

Ā 

AstraZeneca (UK): Acquisition of Alexion Pharmaceuticals (USA)Changes in FTSE UK Index Series

15 July 2021

Subject to the completion of the cash and stock acquistion of Alexion Pharmaceuticals (USA, non-constituent) by AstraZeneca (UK, constituent), please see details of affected indexes and effective dates below:

Ā 

Ā 

Index

Effective FromStart of Trading

FTSE 100 Index

21 July 2021

FTSE 350 Index

21 July 2021

FTSE All-Share Index

21 July 2021

FTSE 350 Higher Yield Index

21 July 2021

Techmark All Share Index

21 July 2021

Ā 

Ā 

Ā 

Ā 

Ā 

Ā 

Ā 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 4563 6346

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

Ā 

Alternatively please visit our website at www.ftserussell.com

Ā 

Terms of Use | Copyright Ā© 2021 FTSE Russell

Ā 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
FTSSFFFMIEFSEFW
141516171819202122
Date   Source Headline
16th Oct 20187:00 amRNSFDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 20183:00 pmRNSTotal Voting Rights
1st Oct 20187:00 amRNSAtacand Agreement with Cheplapharm Completed
28th Sep 20184:00 pmRNSPrevious Announcement Regarding Appointment Of NED
25th Sep 20181:15 pmRNSOverall survival data for Imfinzi: Stage III NSCLC
24th Sep 20184:10 pmRNSEMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 20187:00 amRNSFarxiga gets positive result in DECLARE-TIMI 58
14th Sep 20187:00 amRNSFDA approves AZ's Lumoxiti in hairy cell leukaemia
7th Sep 20187:00 amRNSTezepelumab FDA Breakthrough Therapy Designation
6th Sep 20187:00 amRNSDirectorate Change
3rd Sep 20183:00 pmRNSTotal Voting Rights
31st Aug 20187:00 amRNSAstraZeneca Update on Anifrolumab in SLE
30th Aug 20187:00 amRNSEC approves Bydureon BCise device for T2 diabetes
23rd Aug 20187:00 amRNSAstraZeneca PIIIb trial update for Bevespi in COPD
21st Aug 20187:00 amRNSAZ's Tagrisso approved in Japan for 1st-line NSCLC
15th Aug 20187:00 amRNSAstraZeneca prices a $3bn bond issue
3rd Aug 20187:00 amRNSEMA grants OD for selumetinib in NF1
1st Aug 20183:00 pmRNSTotal Voting Rights
27th Jul 20182:00 pmRNSCHMP recommends Imfinzi for Stage III nsclc
26th Jul 20187:00 amRNSAZN: H1 2018 Results
24th Jul 20187:00 amRNSAtacand to be divested to Cheplapharm in Europe
18th Jul 20184:11 pmRNSHolding(s) in Company
18th Jul 201812:00 pmRNSHolding(s) in Company
2nd Jul 20183:00 pmRNSTotal Voting Rights
2nd Jul 20187:00 amRNSLynparza approved in Japan for BRCAm breast cancer
2nd Jul 20187:00 amRNSImfinzi approved in Japan for Stage III nsclc
29th Jun 20183:00 pmRNSBydureon receives positive CHMP opinion for BCise
28th Jun 20181:30 pmRNSAZ and Luye Pharma complete agreement for Seroquel
27th Jun 20187:00 amRNSLynparza: significant PFS 1st-line ovarian cancer
26th Jun 20187:00 amRNSBoard Committee Changes
22nd Jun 20187:00 amRNSPublication of a Prospectus
12th Jun 20187:00 amRNSUpdate: lanabecestat Phase III Alzheimer's trials
8th Jun 20185:30 pmRNSEU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
8th Jun 20187:00 amRNSDirector Declaration
1st Jun 20183:00 pmRNSBlock listing Interim Review
1st Jun 20183:00 pmRNSTotal Voting Rights
1st Jun 201811:00 amRNSDirector Declaration
30th May 20187:00 amRNSUpdate on TERRANOVA PIII trial for Fasenra in COPD
25th May 20187:00 amRNSAZ's Imfinzi: significant OS in Stage III nsclc
21st May 20187:00 amRNSAZ regulatory submission in Japan for Forxiga
21st May 20187:00 amRNSUS FDA approves Lokelma for adult hyperkalaemia
18th May 20185:30 pmRNSResult of AGM
18th May 20187:00 amRNSAZN: Q1 2018 Results
11th May 20187:00 amRNSAstraZeneca update on Fasenra PIII trial in COPD
8th May 201811:00 amRNSEMA approves Lynparza: maintenance ovarian cancer
8th May 20187:00 amRNSAZ and Luye Pharma enter agreement for Seroquel
4th May 201812:00 pmRNSDirector Declaration
1st May 20183:00 pmRNSTotal Voting Rights
27th Apr 201812:30 pmRNSAZ: positive CHMP for Tagrisso first-line nsclc
24th Apr 20187:00 amRNSAstraZeneca:high level results of the ARCTIC trial
141516171819202122

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
HFD
Halfords
LSE
-0.33%
JMBG
Jh Mbs Gbph D
LSE
-0.40%
JSHY
Jh Us Shy Ua
LSE
-0.15%
APAX
Apax Global Alpha
LSE
0.00%
ALAI
ALAI.L
LSE
0.00%
Trending
ITM
Itm Power
LSE
-10.85%
PPP
Pennpetro Energy
LSE
0.00%
GST
GSTechnologies
LSE
8.11%
NANO
Nanoco
LSE
-10.69%
EZJ
easyJet
LSE
0.34%